Table 2.
Univariate and multivariate analysis of factors according to PFS in AGC patients treated with anti-PD-1 drugs in the first-line therapy.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (years) | ||||
| ≤65 | 1 (reference) | |||
| >65 | 1.183 (0.513-2.728) | 0.694 | – | – |
| Gender | ||||
| Male | 1 (reference) | |||
| Female | 0.964 (0.506-1.918) | 0.964 | – | – |
| Differentiation | ||||
| Poor | 1 (reference) | |||
| Moderate or well | 0.731 (0.342-1.562) | 0.416 | – | – |
| Location | 0.355 | |||
| Upper | 1 (reference) | |||
| Middle | 2.225 (0.906-5.464) | 0.081 | – | – |
| Low | 1.615 (0.680-3.839) | 0.278 | – | – |
| Others | 1.356 (0.429-4.284) | 0.603 | – | – |
| Metastatic site | ||||
| Peritoneal metastasis | ||||
| Negative | 1 (reference) | 1 (reference) | ||
| Positive | 2.417 (1.235-4.731) | 0.008 | 1.448 (0.638-3.287) | 0.376 |
| Liver metastasis | ||||
| Negative | 1 (reference) | |||
| Positive | 1.714 (0.870-3.777) | 0.116 | – | – |
| Lymph node metastasis | ||||
| Negative | 1 (reference) | |||
| Positive | 0.833 (0.378-1.835) | 0.650 | – | – |
| Lung metastasis | ||||
| Negative | 1 (reference) | 1 (reference) | ||
| Positive | 2.512 (1.016-6.209) | 0.039 | 1.617 (0.633-4.131) | 0.315 |
| Number of metastatic sites | ||||
| ≤2 | 1 (reference) | 1 (reference) | ||
| ≥3 | 3.155 (1.601-6.216) | <0.001 | 3.155 (1.601-6.216) | 0.001 |
| ECOG PS | ||||
| 0-1 | 1 (reference) | |||
| ≥2 | 2.901 (0.684-12.312) | 0.130 | – | – |
| First line chemotherapeutic regimen | 0.364 | |||
| Fluorouracil+Platinum | 1 (reference) | |||
| Fluorouracil+Taxanes | 1.142 (0.394-3.308) | 0.807 | – | – |
| Others | 1.707 (0.809-3.602) | 0.160 | – | – |
| Alcohol Consumption | ||||
| Abstinence or low risk | 1 (reference) | |||
| Hazardous or harmful | 1.097 (0.426-2.821) | 0.848 | – | – |
| NLR | ||||
| ≤3.11 | 1 (reference) | |||
| >3.11 | 1.627 (0.853-3.103) | 0.136 | – | – |
| PLR | ||||
| ≤243.33 | 1 (reference) | |||
| >243.33 | 1.987 (0.973-4.057) | 0.055 | – | – |
| MLR | ||||
| ≤0.20 | 1 (reference) | |||
| >0.20 | 1.958 (0.814-4.707) | 0.126 | – | – |
| dNLR | ||||
| ≤2.09 | 1 (reference) | |||
| >2.09 | 1.694 (0.888-3.232) | 0.106 | – | – |
| SII | ||||
| ≤1140.91 | 1 (reference) | |||
| >1140.91 | 1.812 (0.853-3.848) | 0.117 | – | – |
| LDH | ||||
| ≤250 | 1 (reference) | |||
| >250 | 1.167 (0.561-2.429) | 0.679 | – | – |
| CEA | ||||
| ≤5 | 1 (reference) | |||
| >5 | 0.746 (0.354-1.571) | 0.439 | – | – |
| CA199 | ||||
| ≤27 | 1 (reference) | |||
| >27 | 1.048 (0.494-2.224) | 0.903 | – | – |
| CA724 | ||||
| ≤8.2 | 1 (reference) | |||
| >8.2 | 0.858 (0.352-2.090) | 0.736 | – | – |
| Molecular classification | 0.988 | |||
| HER negative | 1 (reference) | |||
| HER positive | 0.973 (0.295-3.207) | 0.965 | – | – |
| Unknown | 1.067 (0.441-2.582) | 0.886 | – | – |